The global endometriosis market size was USD 2060.1 Million in 2020 and is expected to register a revenue CAGR of 2.6% during the forecast period. Key factors driving global market revenue growth are increasing prevalence of this condition across the globe, rising focus on women’s health, and availability of novel drugs and advanced treatment for endometriosis.
Endometriosis is a progressive inflammatory disease in which tissues lining the uterus grow outside the uterine cavity, causing irritation, and scar tissue formation within the pelvis and other reproductive organs. This formation is called endometrial implants and it grows, bleeds, and breaks during each menstrual cycle just like endometrium but remains in the body forming cysts and lesions on ovary. Though endometriosis growths are non-cancerous, these are likely to block fallopian tubes and form scar tissues, and also cause problems related to bladders and intestines.
Endometriosis is one of the most common chronic gynecological conditions seen in around 11% of females between age of 15 – 44 across the globe, affecting women’s quality of life along with reproductive functions resulting in fatigue, depression, nausea, and impaired social function. Symptoms of this condition include severe pain during periods, excessive bleeding, painful urination, bowel movements, severe pain during sexual intercourse, chronic pelvic pain, and abdominal bloating. It can also cause infertility due to this disorder and can effect on pelvic cavity, fallopian tubes and ovaries. It can result in to certain risk factors including short menstrual cycles, low body mass index, uterine abnormalities, and menopause at an older age. Additionally, comorbidities such as increased risk of cardiovascular diseases, autoimmune diseases, and ovarian cancer can be associated with this condition.
Request a Sample@ https://qyresearchmedical.com/sample/118975
Severity of endometriosis is decided depending upon location, size, depth, and amount of tissue.
- Stage I-presence of few lesions with no scars
- Stage II-consists of more lesions, with some scar tissue
- Stage III-presence of deep implants and small cysts
- Stage IV-severe with thick adhesions and deep implants along with large cysts on one or both the ovaries
Though this condition cannot be cured completely, various treatment surgeries such as laparoscopy, laparotomy, and pelvic nerves surgery can be performed and hormonal therapies including birth control pills, Gonadotropin Releasing Hormone agonists and antagonists, progestin can be given to treat patients depending on severity of the condition.
Every year, the month of March is celebrated as Endometriosis Awareness Month across the globe with an aim to raise awareness about the disorder, highlight the consequences of living with this condition and provide an opportunity to patients to play an active role in making a difference. Various organizations come forward to spread awareness through activities such as educational programs, fundraising, and marches where well-known healthcare specialists talk about common endometriosis stigma, and importance of early diagnosis and treatment.
Market Dynamics:
Drivers: Increasing research and development in the field and high focus on spreading awareness regarding the condition are factors driving market growth
Revenue growth of the global market is significantly driven by factors such as increasing number of patients diagnosed with this disorder globally, high number of women within the reproductive age group, and increasing research-based activities to develop more effective drugs for treatment. In addition, government initiatives on improving health of women and efforts by public and private organizations to create awareness about the condition and importance of early diagnosis through social media and campaigns are boosting global endometriosis market growth.
High demand for hormone therapeutics for treatment, rising funds for improving healthcare infrastructure and facilities, availability of various patient-assistance programs to minimize the cost burden on patients, and increasing focus of manufacturers to develop high efficiency therapeutics to cater to unmet treatment needs are also supporting market revenue growth.
Moreover, increasing demand for non-invasive diagnosis procedures, increasing prevalence of various gynecological diseases, and ongoing research activities for developing novel effective drugs to overcome side effects of the existing drugs is expected to create lucrative revenue growth opportunities for major players and new entrants in the global endometriosis market between 2021 and 2028.
Restraints: Lack of non-invasive diagnostics tests is a key factor hampering market growth
The global endometriosis market growth is substantially hampered due to certain unfavorable factors such as unavailability of non-invasive diagnostics tests, dearth of skilled healthcare professionals, and lack of advanced treatment facilities in certain developing and underdeveloped countries.
Other factors such as high cost of advanced therapeutic drugs and requirement of high funds for developing novel drugs can hamper market revenue growth to a certain extent during the forecast period. Moreover, occurrence of possible side effects such as hot flashes, headache, joint and muscle stiffness, vaginal dryness after stopping Gonadotropin Releasing Hormone (GnRH) medications is another factor that could hamper market growth going ahead.
Key Takeaways:
Diagnosis Outlook:
On the basis of diagnosis, the global endometriosis market is segmented into ultrasound, pelvic exam, laparoscopy, Magnetic Resonance Imaging (MRI), hysteroscopy, and sonohysterography. Among these, the laparoscopy segment is expected to account for significantly larger revenue share over the forecast period owing to increasing patient pool across the globe, availability of advanced laparoscopic instruments and procedures, high preference for minimally invasive procedures, and rising awareness about effectiveness of the surgery. Laparoscopy is one of the most common, low risk, and minimally invasive procedures for diagnosis and removal of mild to moderate endometriosis. In laparoscopy, a thin, lighted viewing instrument, laparoscope, is inserted into the abdomen through a small incision that provides accurate information about the size, location, and extent of the endometrial implants. This allows the specialist to view internal organs, take a sample, or remove visible endometriosis implants and possible scar tissues casing infertility or pain.
The Magnetic Resonance Imaging (MRI) segment is expected to register rapid revenue CAGR over the forecast period. MRI helps in surgical planning by detecting sites of deep endometriosis in the pelvis. It used a magnetic field and radio waves to offer detailed images of tissues and organs, along with size and location of implants.
Drug Type Outlook:
Based on drug type, the global endometriosis market is segmented into NSAIDs, gonadotropins releasing hormone agonists, progestin, and oral contraceptive pills. The oral contraceptive pills segment is expected to register fastest revenue CAGR between 2021 and 2028 as oral contraceptives are easily available, are effective in preventing recurrence of endometriosis lesions, and capable of eliminating extreme pelvic pain. Birth control pills with high-level progestin are most effective in reducing pain as these can prevent endometrial cells from shedding and reducing irritation and inflammation.
The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is expected to account for largest revenue share during the forecast period. This can be attributed to extensive usage of NSAIDs for relieving pain caused due to the condition. NSAIDs are commonly used as a first-line treatment for women suffering from the condition as these work by prohibiting the production and release of prostaglandins that normally cause pain, inflammation, and swelling during periods in women suffering from the disorder. Aspirin, ibuprofen, and naproxen are some of the commonly available over-the-counter NSAIDs.
Treatment Outlook:
The global endometriosis market is segmented into hormonal therapy, and pain management, based on treatment. The hormonal therapy segment is expected to register rapid revenue growth over the forecast period. Rapid revenue growth is attributed to factors such as increasing demand for hormone-based therapies, rising prevalence of the condition across the globe, and high usage of hormone therapy as first-line therapy. In addition, high treatment efficiency, easy availability of various hormonal medicines in pharmacies, drugstores and increasing focus on developing more effective hormone-based therapies are factors boosting revenue growth of the segment.
Supplement hormones at times are effective in reducing the pain caused during endometriosis. Thus hormonal therapy is recommended as a primary option to treat pain. These hormones can be administered orally in the form of a pill, injection, or nasal spray. The hormone treatment stops production of hormones and usually prevents ovulation. It also slows local activities and growth of endometrium and endometrial lesions and stops new areas from growing. Some of the commonly used hormonal therapies include Gonadotropin Releasing Hormone (GnRH) medicines, birth control pills, and progesterone, and progestin.
End Use Outlook:
Based on end use, the global endometriosis market is segmented into hospitals, pharmacies, drugstores, and e-commerce. Among these, the drugstore segment accounted for largest revenue share in 2020 and is expected to account for significant revenue share over the forecast period. Factors such as increasing prevalence of the condition, availability of various prescription drugs, and over-the-counter medicines for primary endometriosis treatment are supporting revenue growth of the segment.
The hospital segment is expected to register highest revenue CAGR between 2021 and 2030 owing to factors such as high patient pool in hospitals, high preference for hospital pharmacies due to easy availability of over-the-counter and prescription drugs for the disorder.
Regional Outlook:
North America market is expected to account for largest revenue share in the global market between 2021 and 2028 owing to factors such as high prevalence of the disorder, presence of well-developed healthcare facilities, rising number of females of reproductive age group, increasing investments in women’s healthcare services, and rapid advancements in endometriosis surgical procedures and devices, and treatment. In addition, availability of advanced treatment, increasing number of drug approvals, rising public awareness, presence of some of the major players, increasing focus on spreading awareness regarding the condition among population, along with available therapies and treatment, and increasing focus on developing therapeutically advanced treatments are factors boosting revenue growth of the market in North America.
The market in Asia Pacific is expected to register rapid revenue CAGR over the forecast period. Rapid revenue growth is attributed to factors such as high prevalence of the condition, favorable government initiatives, rising healthcare expenditure, and increasing focus on improving women’s health. Moreover, ongoing research on advanced treatments of the condition and increasing efforts by public and private sectors to create public awareness about endometriosis through various campaigns are factors expected to continue to drive Asia Pacific market growth going ahead.
Competitive Landscape:
The global market is extremely competitive and consists of various key players at regional and global levels. Major players are focused on product development and are adopting various strategies such as mergers and acquisitions, collaborations, joint ventures, partnerships, and investments in research and development activities to expand their product portfolio and strengthen their market positions. AbbVie Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals, Debiopharm International SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Meditrina Pharmaceuticals Inc., Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, Neurocrine Biosciences, Inc., Astellas Pharma Inc., Evotec AG, Addex Therapeutics, Kissei Pharmaceutical Co., Ltd., ElexoPharm, EndoCeutics, Gedeon Richter Plc., Myovant Sciences, Mayne Pharma Group Ltd., and Merck and Co. Inc. are some of the key players operating in the global market.
Strategic Developments:
- In March 2020, Gedeon Richter Plc. and Myovant Sciences announced license agreement to commercialize relugolix combination tablet and uterine fibroids in Russia, Australia and New Zealand.
- In September 2021, Kissei Pharmaceutical Co., Ltd. has entered into a license agreement with Bio Genuine for license development and commercialization rights for GnRH antagonist Linzagolix in China. Linzagolix is a novel GnRH receptor antagonist administered orally, that provides effective management of endometriosis, uterine fibroids and heavy menstrual bleeding.
Pipeline Analysis:
Pfizer and Myovant Sciences announced that US FDA has agreed to review Myfembree (relugolix 40 mg, norethindrone acetate 0.5mg and estradiol 1 mg) a supplemental New Drug Application (sNDA) for managing moderate to severe endometriosis pain. The sNDA submission is supported by results from Phase III SPIRIT program and the application has been set for May 6, 2022 under prescription drug user free act.
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of the market trends in each of the sub-segments from 2022 to 2030. For the purpose of this report, Reports and Data has segmented the global endometriosis market based on diagnosis, drug type, treatment, end use, and region:
Endometriosis Market Report Scope
Segments covered By Diagnosis Outlook, Drug Type Outlook, Treatment Outlook, Regional Outlook
By Diagnosis Outlook
Ultrasound
Pelvic Exam
Laparoscopy
Magnetic Resonance Imaging (MRI)
Hysteroscopy
Sonohysterography
By Drug Type Outlook
NSAIDs
Gonadotropins Releasing Hormone Agonists
Progestin
Oral Contraceptive Pills
By Treatment Outlook
Hormonal Therapy
Pain Management
By End Use Outlook
Hospital
Pharmacies
Drugstores
E-commerce
Regional scope
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118975/1500
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/